QT Prolongation Risk with Escitalopram and Trazodone

Regulatory Actions and Evidence

• The FDA and European Medicines Agency have limited the maximum recommended doses of escitalopram due to QT prolongation concerns, with further dose reductions required for patients older than 60 years 1, 2
• The European Heart Journal guidelines recommend avoiding treatment with more than one drug prolonging the QT interval 1, 2

Clinical Risk Factors

• SSRIs, including escitalopram, significantly increase the risk of cardiac arrest (OR 1.21) in a Danish nationwide registry study 2

Combined Use Considerations

• The combination of escitalopram and trazodone creates additive QT prolongation risk and should be avoided when possible, as both drugs prolong the QT interval through different mechanisms 1, 2
• The risk of arrhythmia increases with each additional QT-prolonging agent 4

Clinical Management Algorithm

• Obtain baseline ECG before initiating either medication, and check serum potassium and magnesium levels and correct any deficiencies before drug administration 1, 2, 5
• Perform follow-up ECG within 7-30 days after initiation and after any dose changes, and discontinue medication immediately if QTc exceeds 500 ms or increases by >60 ms from baseline 1, 2, 5

Individual Susceptibility

• Older age increases vulnerability to QT prolongation, with a mean age of 74 years in SSRI users with cardiac arrest 2
• Women are at higher risk for QT prolongation and torsades de pointes 5